For instance, in PD-L2-overexpressing HCC, post-STRIDE treatment with nivolumab plus ipilimumab could be expected to yield therapeutic benefit following nonresponse to durvalumab plus tremelimumab. The gene discussed is PDCD1LG2; the disease is hepatocellular carcinoma.